Represent

Lobbying
Lobbying by Walgreen Company

Lobbying Relationship

Client

Walgreen Company

More records

Lobbying firm

Walgreen Company

More records

H.R. 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act: Issues related to access to pharmacist services.

Duration: May 19, 2006 to present

General Issues: Pharmacy, Consumer Issues/Safety/Protection, Medicare/Medicaid, Health Issues, Law Enforcement/Crime/Criminal Justice, Taxation/Internal Revenue Code, Alcohol & Drug Abuse, Labor Issues/Antitrust/Workplace, Financial Institutions/Investments/Securities, Banking, Budget/Appropriations, Copyright/Patent/Trademark, Disaster Planning/Emergencies, Food Industry (Safety, Labeling, etc.), Homeland Security, Immigration, Transportation, Trucking/Shipping, Waste (hazardous/solid/interstate/nuclear)

Spending: about $41,490,000 (But it's complicated. Here's why.)

Agencies lobbied since 2006: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), White House Office, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), U.S. Senate,, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Federal Trade Commission (FTC), Defense - Dept of (DOD), Justice - Dept of (DOJ), Executive Office of the President (EOP),

Bills mentioned

H.R.592: Pharmacy and Medically Underserved Areas Enhancement Act

Sponsor: Brett Guthrie (R-Ky.)

S.109: Pharmacy and Medically Underserved Areas Enhancement Act

Sponsor: Charles E. Grassley (R-Iowa)

H.R.3528: Every Prescription Conveyed Securely Act

Sponsor: Katherine Clark (D-Mass.)

H.R.10: Financial CHOICE Act of 2017

Sponsor: Jeb Hensarling (R-Texas)

S.314: Pharmacy and Medically Underserved Areas Enhancement Act

Sponsor: Charles E. Grassley (R-Iowa)

H.R.592: Pharmacy and Medically Underserved Areas Enhancement Act

Sponsor: Brett Guthrie (R-Ky.)

S.524: Comprehensive Addiction and Recovery Act of 2016

Sponsor: Sheldon Whitehouse (D-R.I.)

H.R.6: 21st Century Cures Act

Sponsor: Fred Upton (R-Mich.)

H.R.1021: Protecting the Integrity of Medicare Act of 2015

Sponsor: Kevin Brady (R-Texas)

S.776: Medication Therapy Management Empowerment Act of 2015

Sponsor: Pat Roberts (R-Kan.)

S.754: To improve cybersecurity in the United States through enhanced sharing...

Sponsor: Richard M. Burr (R-N.C.)

H.R.4190: To amend title XVIII of the Social Security Act to provide for coverage...

Sponsor: Brett Guthrie (R-Ky.)

S.621: Safe Prescribing Act of 2013

Sponsor: Joe Manchin III (D-W.Va.)

H.R.1285: To amend the Controlled Substances Act to make any substance containing...

Sponsor: Vern Buchanan (R-Fla.)

S.557: Medication Therapy Management Empowerment Act of 2013

Sponsor: Kay Hagan (D-N.C.)

H.R.1024: Medication Therapy Management Empowerment Act of 2013

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.867: Medicare Prescription Drug Program Integrity and Transparency Act of 2013

Sponsor: Mark Pryor (D-Ark.)

S.2862: Regulatory Transparency, Patient Access, and Effective Drug Enforcement...

Sponsor: Orrin G. Hatch (R-Utah)

H.R.4709: Ensuring Patient Access and Effective Drug Enforcement Act of 2014

Sponsor: Tom Marino (R-Pa.)

S.336: Marketplace Fairness Act of 2013

Sponsor: Michael B. Enzi (R-Wyo.)

H.R.4069: Ensuring Patient Access and Effective Drug Enforcement Act of 2013

Sponsor: Tom Marino (R-Pa.)

S.959: Pharmaceutical Quality, Security, and Accountability Act

Sponsor: Tom Harkin (D-Iowa)

S.957: Drug Supply Chain Security Act

Sponsor: Michael Bennet (D-Colo.)

H.R.1919: Safeguarding America's Pharmaceuticals Act of 2013

Sponsor: Robert E. Latta (R-Ohio)

H.R.684: Marketplace Fairness Act of 2013

Sponsor: Steve Womack (R-Ark.)

H.R.436: Health Care Cost Reduction Act of 2012

Sponsor: Erik Paulsen (R-Minn.)

S.274: Medication Therapy Management Empowerment Act of 2011

Sponsor: Kay Hagan (D-N.C.)

H.R.891: Medication Therapy Management Benefits Act of 2011

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.1971: Pharmacy Competition and Consumer Choice Act of 2011

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.1058: Pharmacy Competition and Consumer Choice Act of 2011

Sponsor: Mark Pryor (D-Ark.)

H.R.4215: Medicare Pharmacy Transparency and Fair Auditing Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.6638: S.A.F.E. Compounded Drugs Act of 2012

Sponsor: Rosa DeLauro (D-Conn.)

H.R.3179: Marketplace Equity Act of 2011

Sponsor: Steve Womack (R-Ark.)

S.1832: Marketplace Fairness Act

Sponsor: Michael B. Enzi (R-Wyo.)

H.R.5853: Gray Market Drug Reform and Transparency Act of 2012

Sponsor: Elijah E. Cummings (D-Md.)

H.R.3026: Safeguarding America's Pharmaceuticals Act of 2011

Sponsor: Jim Matheson (D-Utah)

H.R.4223: SAFE DOSES Act

Sponsor: F. James Sensenbrenner (R-Wis.)

S.1002: Safe Doses Act

Sponsor: Charles E. Schumer (D-N.Y.)

H.R.2529: Restoring Access to Medication Act

Sponsor: Lynn Jenkins (R-Kan.)

S.1368: Restoring Access to Medication Act

Sponsor: Pat Roberts (R-Kan.)

H.R.5651: Food and Drug Administration Reform Act of 2012

Sponsor: Fred Upton (R-Mich.)

H.R.5842: Restoring Access to Medication Act of 2012

Sponsor: Lynn Jenkins (R-Kan.)

S.3187: Food and Drug Administration Safety and Innovation Act

Sponsor: Tom Harkin (D-Iowa)

S.2516: Food and Drug Administration Safety and Innovation Act

Sponsor: Tom Harkin (D-Iowa)

H.R.1936: Medicare Access to Diabetes Supplies Act of 2011

Sponsor: Aaron Schock (R-Ill.)

H.R.2195: Medicare Home Infusion Therapy Coverage Act of 2011

Sponsor: Eliot L. Engel (D-N.Y.)

S.1203: Medicare Home Infusion Therapy Coverage Act of 2011

Sponsor: Olympia J. Snowe (R-Maine)

H.R.3342: Affordable Medicines Utilization Act of 2011

Sponsor: Charles F. Bass (R-N.H.)

S.1356: Affordable Medicines Utilization Act of 2011

Sponsor: Scott Brown (R-Mass.)

H.R.4095: Online Pharmacy Safety Act

Sponsor: Bill Cassidy (R-La.)

S.1584: Drug Safety and Accountability Act of 2011

Sponsor: Michael Bennet (D-Colo.)

H.R.605: Patients' Freedom to Choose Act

Sponsor: Erik Paulsen (R-Minn.)

S.312: Patients' Freedom to Choose Act

Sponsor: Kay Bailey Hutchison (R-Texas)

H.R.1540: National Defense Authorization Act for Fiscal Year 2012

Sponsor: Howard P. McKeon (R-Calif.)

S.981: National Defense Authorization Act for Fiscal Year 2012

Sponsor: Carl Levin (D-Mich.)

H.R.2010: Family and Retirement Health Investment Act of 2011

Sponsor: Erik Paulsen (R-Minn.)

S.1098: Family and Retirement Health Investment Act of 2011

Sponsor: Orrin G. Hatch (R-Utah)

H.R.2267: Home Health Care Planning Improvement Act of 2011

Sponsor: Greg Walden (R-Ore.)

S.227: Home Health Care Planning Improvement Act of 2011

Sponsor: Susan Collins (R-Maine)

H.R.5: Protecting Access to Healthcare Act

Sponsor: Phil Gingrey (R-Ga.)

S.575: Debit Interchange Fee Study Act of 2011

Sponsor: Jon Tester (D-Mont.)

H.R.1081: Consumers Payment System Protection Act

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.2: Repealing the Job-Killing Health Care Law Act

Sponsor: Eric Cantor (R-Va.)

H.RES.9: Instructing certain committees to report legislation replacing the...

Sponsor: David Dreier (R-Calif.)

H.R.1041: FIMBA

Sponsor: Glenn Thompson (R-Pa.)

S.1232: Pharmaceutical Market Access and Drug Safety Act of 2009

Sponsor: Byron L. Dorgan (D-N.D.)

H.R.1298: Pharmaceutical Market Access and Drug Safety Act of 2009

Sponsor: Marion Berry (D-Ark.)

H.R.5809: Diesel Emissions Reduction Act of 2010

Sponsor: Jay Inslee (D-Wash.)

S.3397: Secure and Responsible Drug Disposal Act of 2010

Sponsor: Amy Klobuchar (D-Minn.)

S.510: FDA Food Safety Modernization Act

Sponsor: Richard J. Durbin (D-Ill.)

S.470: Combating Organized Retail Crime Act of 2009

Sponsor: Richard J. Durbin (D-Ill.)

H.R.5932: Organized Retail Theft Investigation and Prosecution Act of 2010

Sponsor: Robert C. Scott (D-Va.)

H.R.3590: Patient Protection and Affordable Care Act

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.3108: Medication Therapy Management Benefits Act of 2009

Sponsor: Mike Ross (D-Ark.)

S.3543: Medication Therapy Management Expanded Benefits Act of 2010

Sponsor: Kay Hagan (D-N.C.)

S.3772: Paycheck Fairness Act

Sponsor: Harry Reid (D-Nev.)

H.R.4173: Dodd-Frank Wall Street Reform and Consumer Protection Act

Sponsor: Barney Frank (D-Mass.)

S.3217: Restoring American Financial Stability Act of 2010

Sponsor: Christopher J. Dodd (D-Conn.)

S.391: Healthy Americans Act

Sponsor: Ron Wyden (D-Ore.)

H.R.1321: Healthy Americans Act

Sponsor: Anna G. Eshoo (D-Calif.)

S.525: Pharmaceutical Market Access and Drug Safety Act of 2009

Sponsor: Byron L. Dorgan (D-N.D.)

H.R.759: Food and Drug Administration Globalization Act of 2009

Sponsor: John D. Dingell (D-Mich.)

S.1383: Dextromethorphan Abuse Reduction Act of 2009

Sponsor: Richard J. Durbin (D-Ill.)

H.R.1173: Organized Retail Crime Act of 2009

Sponsor: Brad Ellsworth (D-Ind.)

H.R.1166: E-fencing Enforcement Act of 2009

Sponsor: Robert C. Scott (D-Va.)

H.R.4011: Organized Retail Crime Prevention and Enforcement Act of 2009

Sponsor: Lamar Smith (R-Texas)

H.R.203: Medicare Fraud Prevention Act of 2009

Sponsor: Cliff Stearns (R-Fla.)

H.R.1586: FAA Air Transportation Modernization and Safety Improvement Act

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.1765: To amend title XVIII of the Social Security Act with respect to payment...

Sponsor: Doris Matsui (D-Calif.)

S.956: Preserve Patient Access to Reputable DMEPOS Providers Act of 2009

Sponsor: Jon Tester (D-Mont.)

H.R.1970: Preserve Patient Access to Reputable DMEPOS Providers Act of 2009

Sponsor: Zack Space (D-Ohio)

H.R.574: Medicare Home Infusion Therapy Coverage Act of 2009

Sponsor: Eliot L. Engel (D-N.Y.)

S.254: Medicare Home Infusion Therapy Coverage Act of 2009

Sponsor: Blanche Lincoln (D-Ark.)

H.R.5597: To establish a Medicare patient IVIG access demonstration project.

Sponsor: Doris Matsui (D-Calif.)

H.R.4213: Unemployment Compensation Extension Act of 2010

Sponsor: Charles B. Rangel (D-N.Y.)

S.182: Paycheck Fairness Act

Sponsor: Hillary Rodham Clinton (D-N.Y.)

H.R.12: Paycheck Fairness Act

Sponsor: Rosa DeLauro (D-Conn.)

H.R.1409: Employee Free Choice Act of 2009

Sponsor: George Miller (D-Calif.)

S.560: Employee Free Choice Act of 2009

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.4851: Continuing Extension Act of 2010

Sponsor: Sander M. Levin (D-Mich.)

H.R.1259: Dextromethorphan Distribution Act of 2009

Sponsor: Fred Upton (R-Mich.)

H.R.3962: Preservation of Access to Care for Medicare Beneficiaries and Pension...

Sponsor: John D. Dingell (D-Mich.)

H.R.2350: Preserving Patient Access to Primary Care Act of 2009

Sponsor: Allyson Y. Schwartz (D-Pa.)

H.R.816: Military Retirees Health Care Protection Act

Sponsor: Chet Edwards (D-Texas)

S.80: Pharmaceutical Market Access Act of 2009

Sponsor: David Vitter (R-La.)

H.R.806: TRICARE Mail-Order Pharmacy Pilot Program Act

Sponsor: Gus Bilirakis (R-Fla.)

H.R.1548: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

S.726: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Charles E. Schumer (D-N.Y.)

H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

H.R.1815: Consumer Product Safety Solutions Act of 2009

Sponsor: Joe L. Barton (R-Texas)

S.882: Drug and Device Accountability Act of 2009

Sponsor: Edward M. Kennedy (D-Mass.)

S.701: Medicare Patient IVIG Access Act of 2009

Sponsor: John Kerry (D-Mass.)

H.R.2002: Medicare Patient IVIG Access Act of 2009

Sponsor: Steve Israel (D-N.Y.)

H.R.3663: To amend title XVIII of the Social Security Act to delay the date on...

Sponsor: Zack Space (D-Ohio)

S.1796: America's Healthy Future Act of 2009

Sponsor: Max Baucus (D-Mont.)

S.1679: Affordable Health Choices Act

Sponsor: Tom Harkin (D-Iowa)

H.R.3200: America's Affordable Health Choices Act of 2009

Sponsor: John D. Dingell (D-Mich.)

H.R.1256: Family Smoking Prevention and Tobacco Control Act

Sponsor: Henry A. Waxman (D-Calif.)

H.R.1: American Recovery and Reinvestment Act of 2009

Sponsor: David R. Obey (D-Wis.)

H.R.570: Protecting Patients and Health Care Act of 2009

Sponsor: Diana DeGette (D-Colo.)

S.1951: Fair Medicaid Drug Payment Act of 2007

Sponsor: Max Baucus (D-Mont.)

H.R.3700: Fair Medicaid Drug Payment Act of 2007

Sponsor: Frank Pallone (D-N.J.)

H.R.3140: Saving Our Community Pharmacies Act of 2007

Sponsor: Nancy E. Boyda (D-Kan.)

S.334: Healthy Americans Act

Sponsor: Ron Wyden (D-Ore.)

S.980: Ryan Haight Online Pharmacy Consumer Protection Act of 2008

Sponsor: Dianne Feinstein (D-Calif.)

H.R.6353: Ryan Haight Online Pharmacy Consumer Protection Act of 2008

Sponsor: Bart Stupak (D-Mich.)

S.3101: Medicare Improvements for Patients and Providers Act of 2008

Sponsor: Max Baucus (D-Mont.)

H.R.6331: Medicare Improvements for Patients and Providers Act of 2008

Sponsor: Charles B. Rangel (D-N.Y.)

S.2408: Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007

Sponsor: John Kerry (D-Mass.)

H.R.2900: Food and Drug Administration Amendments Act of 2007

Sponsor: John D. Dingell (D-Mich.)

H.R.5839: Safeguarding America's Pharmaceuticals Act of 2008

Sponsor: Steve Buyer (R-Ind.)

S.3001: Duncan Hunter National Defense Authorization Act for Fiscal Year 2009

Sponsor: Carl Levin (D-Mich.)

H.R.5658: Duncan Hunter National Defense Authorization Act for Fiscal Year 2009

Sponsor: Ike Skelton (D-Mo.)

S.1693: Wired for Health Care Quality Act

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.6357: PRO(TECH)T Act of 2008

Sponsor: John D. Dingell (D-Mich.)

H.R.6898: Health-e Information Technology Act of 2008

Sponsor: Pete Stark (D-Calif.)

S.1276: Methamphetamine Production Prevention Act of 2008

Sponsor: Richard J. Durbin (D-Ill.)

H.R.2747: Methamphetamine Production Prevention Act of 2007

Sponsor: Keith Ellison (D-Minn.)

H.R.3610: Food and Drug Import Safety Act of 2007

Sponsor: John D. Dingell (D-Mich.)

S.2045: CPSC Reform Act of 2007

Sponsor: Mark Pryor (D-Ark.)

H.R.6491: Organized Retail Crime Act of 2008

Sponsor: Brad Ellsworth (D-Ind.)

S.3434: Combating Organized Retail Crime Act of 2008

Sponsor: Richard J. Durbin (D-Ill.)

H.R.6713: E-fencing Enforcement Act of 2008

Sponsor: Robert C. Scott (D-Va.)

H.R.2914: Medicare IVIG Access Act of 2007

Sponsor: Kevin Brady (R-Texas)

S.2274: Dextromethorphan Abuse Reduction Act of 2007

Sponsor: Joseph R. Biden Jr. (D-Del.)

H.R.3580: Food and Drug Administration Amendments Act of 2007

Sponsor: John D. Dingell (D-Mich.)

S.1082: Food and Drug Administration Revitalization Act

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.5491: Pharmacy Technician Training and Registration Act of 2008

Sponsor: Steven C. LaTourette (R-Ohio)

H.R.5629: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.1956: Patient Protection and Innovative Biologic Medicines Act of 2007

Sponsor: Jay Inslee (D-Wash.)

S.1145: Patent Reform Act of 2007

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.1108: Family Smoking Prevention and Tobacco Control Act

Sponsor: Henry A. Waxman (D-Calif.)

H.R.1: An Act to provide for reconciliation pursuant to titles II and V of the...

Sponsor: Kevin Brady (R-Texas)

S.2460: Every Prescription Conveyed Securely Act

Sponsor: Michael Bennet (D-Colo.)

H.R.6: SUPPORT for Patients and Communities Act

Sponsor: Greg Walden (R-Ore.)

H.R.1034: Phair Pricing Act of 2019

Sponsor: Doug Collins (R-Ga.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

H.R.748: CARES Act

Sponsor: Joe Courtney (D-Conn.)

H.R.6201: Families First Coronavirus Response Act

Sponsor: Nita M. Lowey (D-N.Y.)

H.R.6379: Workforce Emergency Response Act of 2020

Sponsor: Nita M. Lowey (D-N.Y.)

S.3431: INFORM Consumers Act

Sponsor: Bill Cassidy (R-La.)

S.2543: Prescription Drug Pricing Reduction Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

H.R.6573: Help Our Heroes Access Medicine Act of 2020

Sponsor: Lisa Blunt Rochester (D-Del.)

H.R.7756: INFORM Consumers Act

Sponsor: Jan Schakowsky (D-Ill.)

S.936: INFORM Consumers Act

Sponsor: Richard J. Durbin (D-Ill.)

H.R.3554: Pharmacy DIR Reform To Reduce Senior Drug Costs Act

Sponsor: Peter Welch (D-Vt.)

S.1909: Pharmacy DIR Reform To Reduce Senior Drug Costs Act

Sponsor: Jon Tester (D-Mont.)

H.R.5376: Inflation Reduction Act of 2022

Sponsor: John Yarmuth (D-Ky.)

H.R.5502: To require online marketplaces to verify certain information regarding...

Sponsor: Jan Schakowsky (D-Ill.)

H.R.7213: Equitable Community Access to Pharmacist Services Act

Sponsor: Ron Kind (D-Wis.)

H.R.7845: NIH Clinical Trial Diversity Act of 2022

Sponsor: Robin Kelly (D-Ill.)

H.J.RES.7: Relating to a national emergency declared by the President on March 13,...

Sponsor: Paul Gosar (R-Ariz.)

H.R.1613: Drug Price Transparency in Medicaid Act of 2023

Sponsor: Buddy Carter (R-Ga.)

S.127: Pharmacy Benefit Manager Transparency Act of 2023

Sponsor: Maria Cantwell (D-Wash.)

S.2477: Equitable Community Access to Pharmacist Services Act

Sponsor: John Thune (R-S.D.)

H.R.2503: PROTECT Florida Act

Sponsor: Brian Mast (R-Fla.)

S.1701: NIH Clinical Trial Diversity Act of 2023

Sponsor: Robert Menendez (D-N.J.)

H.R.1770: Equitable Community Access to Pharmacist Services Act

Sponsor: Adrian Smith (R-Neb.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist	Covered positions?
Katharine Troller	2013-2015 Legislative Dir, Rep Greg Walden; 2011-2013 Legislative Dir, Rep Rich Nugent & House Rules (shared staff); 2009-2011 Legislative Asst, Rep Ginny Brown-Waite; 2008-2009 Legislative Correspondent, Rep Ginny Brown-Waite 2013-2015 Legislative Dir, Rep Greg Walden; 2011-2013 Legislative Dir, Rep Rich Nugent; 2009-2011 Legislative Asst, Rep Ginny Brown-Waite; 2008-2009 Legislative Correspondent, Rep Ginny Brown-Waite
Edward Kaleta	n/a
Alethia Jackson	n/a
Debbie Garza	n/a
Ed Kaleta	n/a
Katharine Bond	n/a
Katie Troller	n/a
Debra Garza	n/a
Ed Kaletta	n/a
Altheia Jackson	n/a
Heather Smith	n/a
Susan DeVries	n/a
Susie Schulte	n/a
Susie Howard (formerly Schulte)	n/a
Leslie Higgins	n/a
Bryan Schneider	n/a
Samantha Elleson	n/a
Elizabeth Hunger	n/a
Katie Smith	n/a
Madeline Hodge	n/a
Isaac Fordjour	n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

1st Quarter, 2024

Q1 Report

In Q1, Walgreen Company had in-house lobbyists. The report was filed on April 19. Original Filing: 301566137.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2023

Q4 Report

In Q4, Walgreen Company had in-house lobbyists. The report was filed on Jan. 19. Original Filing: 301530904.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2023

Q3 Report

In Q3, Walgreen Company had in-house lobbyists. The report was filed on Oct. 18, 2023. Original Filing: 301505221.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2023

Q2 Report

In Q2, Walgreen Company had in-house lobbyists. The report was filed on July 20, 2023. Original Filing: 301490669.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2023

Q1 Report

In Q1, Walgreen Company had in-house lobbyists. The report was filed on April 20, 2023. Original Filing: 301467760.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2022

Q4 Report

In Q4, Walgreen Company had in-house lobbyists. The report was filed on Jan. 20, 2023. Original Filing: 301442073.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2022

Q3 Report

In Q3, Walgreen Company had in-house lobbyists. The report was filed on Oct. 20, 2022. Original Filing: 301415637.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2022

Registration

2nd Quarter, 2022

Q2 Report

In Q2, Walgreen Company had in-house lobbyists. The report was filed on July 20, 2022. Original Filing: 301395597.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2022

Q1 Report

In Q1, Walgreen Company had in-house lobbyists. The report was filed on April 20, 2022. Original Filing: 301366052.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2021

Q4 Report

In Q4, Walgreen Company had in-house lobbyists. The report was filed on Jan. 20, 2022. Original Filing: 301335679.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2021

Q3 Report

In Q3, Walgreen Company had in-house lobbyists. The report was filed on Oct. 20, 2021. Original Filing: 301311151.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2021

Q2 Report

In Q2, Walgreen Company had in-house lobbyists. The report was filed on July 20, 2021. Original Filing: 301288689.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2021

Q1 Report

In Q1, Walgreen Company had in-house lobbyists. The report was filed on April 20, 2021. Original Filing: 301267646.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2020

Amendment

Walgreen Company amended a lobbying report for in-house lobbying in Q42020 on June 23, 2021 Original Filing: 301272811.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2020

Q4 Report

In Q4, Walgreen Company had in-house lobbyists. The report was filed on Jan. 20, 2021. Original Filing: 301242641.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2020

Q3 Report

In Q3, Walgreen Company had in-house lobbyists. The report was filed on Oct. 20, 2020. Original Filing: 301222385.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2020

Q2 Report

In Q2, Walgreen Company had in-house lobbyists. The report was filed on July 20, 2020. Original Filing: 301198182.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2020

Q1 Report

In Q1, Walgreen Company had in-house lobbyists. The report was filed on April 20, 2020. Original Filing: 301179241.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2019

Q4 Report

In Q4, Walgreen Company had in-house lobbyists. The report was filed on Jan. 20, 2020. Original Filing: 301122625.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2019

Q3 Report

In Q3, Walgreen Company had in-house lobbyists. The report was filed on Oct. 21, 2019. Original Filing: 301076712.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2019

Q2 Report

In Q2, Walgreen Company had in-house lobbyists. The report was filed on July 22, 2019. Original Filing: 301055544.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2019

Q1 Report

In Q1, Walgreen Company had in-house lobbyists. The report was filed on April 22, 2019. Original Filing: 301033962.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2018

Q4 Report

In Q4, Walgreen Company had in-house lobbyists. The report was filed on Jan. 18, 2019. Original Filing: 301009223.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2018

Q3 Report

In Q3, Walgreen Company had in-house lobbyists. The report was filed on Oct. 22, 2018. Original Filing: 300996938.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2018

Q2 Report

In Q2, Walgreen Company had in-house lobbyists. The report was filed on July 20, 2018. Original Filing: 300974946.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2018

Q1 Report

In Q1, Walgreen Company had in-house lobbyists. The report was filed on April 20, 2018. Original Filing: 300956444.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2017

Q4 Report

In Q4, Walgreen Company had in-house lobbyists. The report was filed on Jan. 19, 2018. Original Filing: 300929158.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2017

Q3 Report

In Q3, Walgreen Company had in-house lobbyists. The report was filed on Oct. 20, 2017. Original Filing: 300912426.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2017

Q2 Report

In Q2, Walgreen Company had in-house lobbyists. The report was filed on July 20, 2017. Original Filing: 300894006.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Q1 Report

In Q1, Walgreen Company had in-house lobbyists. The report was filed on April 20, 2017. Original Filing: 300874432.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2016

Q4 Report

In Q4, Walgreen Company had in-house lobbyists. The report was filed on Jan. 20, 2017. Original Filing: 300852939.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2016

Q3 Report

In Q3, Walgreen Company had in-house lobbyists. The report was filed on Oct. 20, 2016. Original Filing: 300835540.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2016

Q2 Report

In Q2, Walgreen Company had in-house lobbyists. The report was filed on July 20, 2016. Original Filing: 300816912.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Q1 Report

In Q1, Walgreen Company had in-house lobbyists. The report was filed on April 20, 2016. Original Filing: 300801772.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2015

Q4 Report

In Q4, Walgreen Company had in-house lobbyists. The report was filed on Jan. 20, 2016. Original Filing: 300782904.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Q3 Report

In Q3, Walgreen Company had in-house lobbyists. The report was filed on Oct. 20, 2015. Original Filing: 300762693.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Registration

2nd Quarter, 2015

Q2 Report

In Q2, Walgreen Company had in-house lobbyists. The report was filed on July 20, 2015. Original Filing: 300744266.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Amendment

Walgreen Company amended a lobbying report for in-house lobbying in Q12015 on April 21, 2015 Original Filing: 300728075.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Q1 Report

In Q1, Walgreen Company had in-house lobbyists. The report was filed on April 20, 2015. Original Filing: 300726083.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2014

Q4 Report

In Q4, WALGREEN CO. had in-house lobbyists. The report was filed on Jan. 20, 2015. Original Filing: 300706774.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Q3 Report

In Q3, WALGREEN CO. had in-house lobbyists. The report was filed on Oct. 20, 2014. Original Filing: 300689268.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2014

Q2 Report

In Q2, WALGREEN CO. had in-house lobbyists. The report was filed on July 21, 2014. Original Filing: 300668293.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2014

Q1 Report

In Q1, WALGREEN CO. had in-house lobbyists. The report was filed on April 21, 2014. Original Filing: 300648041.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2013

Q4 Report

In Q4, WALGREEN CO. had in-house lobbyists. The report was filed on Jan. 21, 2014. Original Filing: 300626442.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Q3 Report

In Q3, WALGREEN CO. had in-house lobbyists. The report was filed on Oct. 21, 2013. Original Filing: 300606024.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2013

Q2 Report

In Q2, WALGREEN CO. had in-house lobbyists. The report was filed on July 22, 2013. Original Filing: 300583706.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Q1 Report

In Q1, WALGREEN CO. had in-house lobbyists. The report was filed on April 19, 2013. Original Filing: 300557134.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2012

Q4 Report

In Q4, WALGREEN CO. had in-house lobbyists. The report was filed on Jan. 18, 2013. Original Filing: 300535074.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting to Part D plan sponsors of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescription drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan or control the costs of such coverage, unless the manager satisfies specific PBM audit and disclosure requirements. H.R. 6638, the Supporting Access to Formulated and Effective (SAFE) Compounded Drugs Act, all provisions requiring compounding pharmacies to register their facility with the FDA, requiring compounded drugs to be labeled appropriately, establishing an FDA database on compounding pharmacies and having the FDA set minimum production standards. Issues relating to regulations that would establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. No specific legislation.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 3179 - the "Market Place Equity Act of 2011," all provisions regarding authorizing states to require all sellers making remote sales to collect and remit sales and use taxes with respect to such sales into the state, without regard to the location of the seller. S. 1832 - the "Marketplace Fairness Act," all provisions regarding authorizing member states under the Streamlined Sales and Use Tax Agreement to require all sellers (minus small seller exception) to collect and remit sales and use taxes with respect to remote sales and allowing a state that is not a member state under the Agreement to require sellers to collect and remit sales and use taxes without respect to remote sales. Issues related to corporate tax reform. No specific legislation.

Agencies Lobbied

Type of Issue

3rd Quarter, 2012

Q3 Report

In Q3, WALGREEN CO. had in-house lobbyists. The report was filed on Oct. 22, 2012. Original Filing: 300522697.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting to Part D plan sponsors of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan or control the costs of such coverage, unless the manager satisfies specific PBM audit and disclosure requirements. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. Issues relating to regulations that would establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. No specific legislation.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2012

Q2 Report

In Q2, WALGREEN CO. had in-house lobbyists. The report was filed on July 20, 2012. Original Filing: 300498576.xml

Lobbying Issues

H.R. 2529/S.1368 - the "Restoring Access to Medication Act," all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that limits payments for medications from health savings accounts, medical savings accounts, and health felxible spending arrangements to only prescriotion drugs or insulin. H.R. 5651 - the FDA Reform Act of 2012, all provisions regarding reauthorizing and establishing new FDA prescription drug user-fee programs and revises requirements related to prescription, pediatric and generic drugs; medical devices; biosimilar biological products; new infectious disease drugs and drug manufacturer reporting. H.R. 5842 - the Restoring Access to Medication Act, all provisions regarding repealing provisions of PPACA that limit payments for medications from health savings accounts and health flexible spending arrangements and reimbursement arrangements to only prescription drugs or insulin. H.R. 436 - the Health Care Cost Reduction Act, all provisions regarding repealing provisions of PPACA that limit payments for medications from health savings accounts and health flexible spending arrangements and reimbursement arrangements to only prescription drugs or insulin. S.3187/S.2516 - the FDA Safety and Innovation Act, all provisions regarding reauthorizing and establishing new FDA prescription drug user-fee programs and revises requirements related to prescription, pediatric and generic drugs; medical devices; biosimilar biological products; new infectious disease drugs and drug manufacturer reporting.

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 274 - the "Medication Therapy Management Empowerment Act of 2011," all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.H.R. 891 - the "Medication Therapy Management (MTM) Benefits Act of 2011," all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. H.R. 1936 - the "Medicare Access to Diabetes Supplies Act of 2011," provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203 - the "Medicare Home Infusion Therapy Coverage Act," provisions related to the Medicare coverage of home infusion therapy and home infusion drugs. H.R. 3342/S. 1356 - the "Affordable Medicines Utilization Act of 2011," all provisions regarding requiring an increase in the quarterly Medicaid payment to a state by 50% of the generic drug utilization savings amount if the state's generic substitution rate for the most recent preceding fiscal year for which data is available is greater than its rate for the most recent second preceding fiscal year for which data is available.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed.H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. H.R. 4095 - the "Online Pharmacy Safety Act," all provisions regarding requiring the U.S. Department of Health and Human Services (HHS) to create a public registry of legitimate online pharmacy websites. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit the PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan, or to control the costs of such coverage, unless the manager satisfies specified PBM audit and disclosure requirements. S. 1584 - the "Drug Safety and Accountability Act," all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2012

Q1 Report

In Q1, WALGREEN CO. had in-house lobbyists. The report was filed on April 20, 2012. Original Filing: 300472985.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," all provisions regarding requiring each contract entered into with a prescripotion drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under each plan. H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annually reporting to Part D plan sponsors number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026 - the "Safeguarding America's Pharmaceutical Act," all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. S. 1584 - the "Drug Safety and Accountability Act," all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug. H.R. 4095 - the "Online Pharmacy Safety Act," all provisions regarding requiring the U.S. Department of Health and Human Services (HHS) to create a public registry of legitimate online pharmacy websites.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2011

Q4 Report

In Q4, WALGREEN CO. had in-house lobbyists. The report was filed on Jan. 20, 2012. Original Filing: 300449782.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 274- the "Medication Therapy Management Empowerment Act of 2011" -all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.H.R. 891- the "Medication Therapy Management (MTM) Benefits Act of 2011" - all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM in Medicare Part D benefit. H.R. 1936 - the "Medicare Access to Diabetes Supplies Act of 2011" - provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203 - the "Medicare Home Infusion Therapy Coverage Act" - provisions related to the Medicare coverage of home infusion therapy and home infusion drugs. H.R. 3342/S. 1356 - the "Affordable Medicines Utilization Act of 2011" - all provisions regarding requiring an increase in the quarterly Medicaid payment to a state by 50% of the generic drug utilization savings amount if the state's generic substitution rate for the most recent preceding fiscal year for which data is available is greater than its rate for the most recent second preceding fiscal year for which data is available.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.1540/S. 981- the "National Defense Authorization Act of FY 2012" - provisions related to the TRICARE pharmacy program. TRICARE-no specific legislation-regarding pharmacy services provided to TRICARE beneficiaries. H.R. 1971- the "Pharmacy Competition and Consumer Choice Act of 2011"- all provisions related to requirement of Pharmacy Benefit Managers annually reporting to Part D plan sponsors number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026- the "Safeguarding America's Pharmaceutical Act."-all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. S. 1584- the "Drug Safety and Accountability Act"- all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2011

Q3 Report

In Q3, WALGREEN CO. had in-house lobbyists. The report was filed on Oct. 20, 2011. Original Filing: 300425971.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.1540/S. 981- the "National Defense Authorization Act of FY 2012"- provisions related to the TRICARE pharmacy program. TRICARE-no specific legislation-regarding pharmacy services provided to TRICARE beneficiaries. H.R. 1971- the "Pharmacy Competition and Consumer Choice Act of 2011"- all provisions related to requirement of Pharmacy Benefit Managers annually reporting to Part D plan sponsors number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026- the "Safeguarding America's Pharmaceutical Act."-all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. S. 1584- the "Drug Safety and Accountability Act"- all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Q2 Report

In Q2, WALGREEN CO. had in-house lobbyists. The report was filed on July 20, 2011. Original Filing: 300400153.xml

Lobbying Issues

H.R. 2- the "Repealing the Job Killing Health Care Law Act"- any discussions or provisions regarding Average Manufacturer's Price (AMP) and medication therapy management (MTM). H.R. 2267/S. 227- the "Home Health Care Planning Improvement Act"- provisions related to payments for home health care services.H. Res. 9- the "Replace" bill- all provisions regarding the instruction of certain committees to report legislation replacing the job-killing health law, specifically with regards to discussions of Average Manufacturer's Price (AMP) and medication therapy management (MTM). H.R. 5-the "Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011"-all provisions regarding capping damages at the greater of $250,000 or double the award of economic damages for certain health providers. H.R. 605/S. 312-the "Patient Freedom to Choose Act"-all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that restrict payments from health flexible spending arrangements for medications to prescription drugs and insulin. H.R. 2010/ S. 1098-the "Family and Retirement Health Investment Act of 2011"- provisions related to payments from a HSA/FSA for prescription and over-the-counter medicine or drugs. P.L. 111-148- the "Patient Protection and Affordable Care Act."-regarding the implementation of regulations of P.L. 111-148 including issues related to Average Manufacturer's Price (AMP), Medication Therapy Management (MTM), and employer coverage mandates.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2011

Q1 Report

In Q1, WALGREEN CO. had in-house lobbyists. The report was filed on April 19, 2011. Original Filing: 300371363.xml

Lobbying Issues

HR. 2- the "Repealing the Job Killing Health Care Law Act"- any discussions or provisions repealing Average Manufacturer's Price (AMP) and medication therapy management (MTM). H. Res. 9- the "Replace" bill- all provisions regarding the instruction of certain committees to report legislation replacing the job-killing health law, specifically with regards to discussions of Average Manufacturer's Price (AMP) and medication therapy management (MTM). HR. 5-the "Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011"-all provisions regarding capping damages at the greater of $250,000 or double the award of economic damages for certain health providers. S. 312/HR.605-the "Patient Freedom to Choose Act"-all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that restrict payments from health flexible spending arrangements for medications to prescription drugs and insulin.

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 274- the "Medication Therapy Management Empowerment Act of 2011" -all provisions regarding amending Part D of Medicare to increase the number of diseases and conditions for which beneficiaries may be targeted for medication therapy management (MTM) services.HR. 891- the "Medication Therapy Management Benefits Act of 2011"- all provisions regarding amending Part D of Medicare to require that the annual comprehensive medication review, including creation of a medication record and a recommended action plan in consultation with the individual and the prescriber; requires medication therapy management (MTM) to include medication reviews person-to-person by a licensed pharmacist offered every quarter and increases the number of diseases and conditions for which beneficiaries may be targeted for MTM services. HR. 1041- the "Fairness in Medicare Bidding Act" - all provisions, regarding the repealing the Medicare Competitive Bidding acquisition program for durable medical equipment and prosthetics, orthotics and supplies (DMEPOS).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2010

Q4 Report

In Q4, WALGREEN CO. had in-house lobbyists. The report was filed on Jan. 20, 2011. Original Filing: 300351009.xml

Lobbying Issues

S. 1232/HR. 1298- the "Pharmaceutical Market Access and Drug Safety Act of 2009"- all provisions; regarding amending the federal food, drug, and cosmetic act to allow importation of prescription drugs by pharmacies. HR 5809 the "Safe Drug Disposal Act of 2010" All provisions regarding permitting an ultimate user who has lawfully obtained a controlled substance to deliver such substance to another person for purpose of disposal. S. 3397 the 'Secure and Responsible Drug Disposal Act of 2010" All provisions regarding allowing an ultimate user of a controlled substance who has lawfully obtained such substance to deliver that substance to another person for disposal. S. 510- the "FDA Food Safety Modernization Act," no specific provisions-regarding any amendments or discussions looking to add language to allow importation of prescription drugs by pharmacies.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2010

Q3 Report

In Q3, WALGREEN CO. had in-house lobbyists. The report was filed on Oct. 20, 2010. Original Filing: 300325944.xml

Lobbying Issues

S. 391/HR. 1321 - the "Healthy American's Act" regarding the role of pharmacy in healthcare and Title VI regarding shared responsibilities.S. 1232/S. 525/HR. 1298 the Pharmaceutical Market Access and Drug Safety Act of 2009 all provisions; regarding amending the federal food, drug, and cosmetic act to allow the importation of prescription drugs by pharmacies. Electronic Prescribing of Controlled Substances regarding the need for the DEA to publish rules that would allow for electronic prescribing of controlled substances no specific legislation. HR. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug and Device Safety all provisions relating to this title on drug and device safety. HR 5809 the "Safe Drug Disposal Act of 2010" All provisions regarding permitting an ultimate user who has lawfully obtained a controlled substance to deliver such substance to another person for purpose of disposal. S. 3397 the 'Secure and Responsible Drug Disposal Act of 2010" All provisions regarding allowing an ultimate user of a controlled substance who has lawfully obtained such substance to deliver that substance to another person for disposal,

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR. 1173 the Organized Retail Crime Act of 2009 all provisions, regarding amending title 18 of the United States Criminal Code to include organized retail crime and imposing requirements on on-line marketplaces to facilitate criminal investigations.S. 470 the Combating Organized Retail Crime Act of 2009 all provisions, regarding amending the criminal code and expanding the definition of transporting and selling stolen goods from a physical or on-line marketplace. HR. 1166 the E-Fencing Enforcement Act of 2009 all provisions, regarding amending the criminal code to impose duty on on-line marketplaces to retain contact information on high volume sellers and disclose that information when evidence is presented by law enforcement that the merchandise is stolen. HR. 4011 -- the "Organized Retail Crime Prevention and Enforcement Act of 2009" -- all provisions, regarding amending the federal criminal code to prohibit the transportation of fraudulently obtained goods valued at $1,000 or more for sale on an online marketplace and the barter or sale of such goods online with knowledge that such goods have been stolen, converted, or taken by fraud. HR 5932 the "Organized Retail Theft Investigation and Prosecution Act" All provisions; regarding establishing the Organized Retail Theft Investigation and Prosecution Unit to investigate and prosecute instances of organized retail theft; assist state and local law enforcement agencies in investigating and prosecuting these crimes, and consults with and advises victims of such crimes.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 3590- the "Patient Protection and Affordable Care Act" regarding the role of pharmacists and the practice of pharmacy in healthcare. HR. 203 the Medicare Fraud Prevention Act of 2009 Section 4 provisions relating to the increased surety bond requirement of suppliers of durable medical equipment. HR. 1586- the "FAA Air Transportation Modernization and Safety Improvement Act" -Title II- all provisions relating to State Fiscal Relief and other provisions. Extend through the first three quarters of 2011 the Federal Medicaid Assistance Percentage (FMAP). Amend title XIX of the Social Security Act to include Medicaid coverage in the Medicaid average manufacturer price any drug that is an inhalation, infusion, instilled, implanted, or injectable drug that is not generally dispensed through a retail pharmacy. HR. 1765 all provisions, regarding amending the Social Security Act with respect to payment for items and services relating to the furnishing of IVIG in a patients home for the treatment of primary immune deficiency disease and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare program. S. 956/HR 1970 the Preserve Patient Access to Reputable DMEPOS Providers Act of 2009 all provisions; regarding exempting unsanctioned State-licensed retail pharmacies from the surety bond requirement under the Medicare Program for suppliers of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS). HR 574/S. 254 the Medicare Home Infusion Therapy Act of 2009 all provisions; regarding amending the Social Security Act to provide for the coverage of home infusion therapy under the Medicare program. HR. 3108 the Medication Therapy Management Benefits Act of 2009, all provisions; regarding amending part D of title XVIII of the Social Security Act to promote medication therapy management under the Medicare part D prescription drug program. HR 5597 - all provisions regarding establishing a Medicare patient IVIG access demonstration project. S. 3543 - the "Medication Therapy Management Expanded Benefits Act of 2010," - all provisions, regarding amending Part D of title XVIII of the Social Security Act to increase the number of diseases and conditions for which beneficiaries may be targeted for medication therapy management services. HR 4213 - the "American Jobs and Closing Tax Loopholes Act of 2010," - section 232 - regarding amending ARRA to extend through December 31, 2010, the increase in the Medicaid federal medical assistance percentage (FMAP).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Q2 Report

In Q2, WALGREEN CO. had in-house lobbyists. The report was filed on July 20, 2010. Original Filing: 300297266.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR. 203 the Medicare Fraud Prevention Act of 2009 Section 4 provisions relating to the increased surety bond requirement of suppliers of durable medical equipment.HR. 1765 all provisions, regarding amending the Social Security Act with respect to payment for items and services relating to the furnishing of IVIG in a patients home for the treatment of primary immune deficiency disease and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare program. S. 956/HR 1970 the Preserve Patient Access to Reputable DMEPOS Providers Act of 2009 all provisions; regarding exempting unsanctioned State-licensed retail pharmacies from the surety bond requirement under the Medicare Program for suppliers of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS). HR 574/S. 254 the Medicare Home Infusion Therapy Act of 2009 all provisions; regarding amending the Social Security Act to provide for the coverage of home infusion therapy under the Medicare program. HR. 3108 the Medication Therapy Management Benefits Act of 2009, all provisions; regarding amending part D of title XVIII of the Social Security Act to promote medication therapy management under the Medicare part D prescription drug program. HR 4851, the "Continuing Extension Act of 2010," - section 4 - provisions relating to amending title XVIII (Medicare) of the Social Security Act to extend through May 31, 2010, the 0% update to the conversion factor in the Medicare physician payment computation. HR 5597 - all provisions regarding establishing a Medicare patient NIG access demonstration project. S. 3543 - the "Medication Therapy Management Expanded Benefits Act of 2010," - all provisions, regarding amending Part D of title XVIII of the Social Security Act to increase the number of diseases and conditions for which beneficiaries may be targeted for medication therapy management services. HR 4213 - the "American Jobs and Closing Tax Loopholes Act of 2010," - section 232 - regarding amending ARRA to extend through December 31, 2010, the increase in the Medicaid federal medical assistance percentage (FMAP). HR 3590 - the Patient Protection and Affordable Care Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2010

Q1 Report

In Q1, WALGREEN CO. had in-house lobbyists. The report was filed on April 20, 2010. Original Filing: 300274884.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 3590, the Patient Protection and Affordable Care Act- regarding redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies- as related to AMPs Federal Upper Limits (FULs), regarding expanding medication therapy management (MTM) services provided by pharmacists and expanding home infusion in Medicare to cover the supplies, equipment and services.H.R. 3962, the Affordable Health Care for America Act- regarding redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies- as related to AMPs Federal Upper Limits (FULs), regarding expanding medication therapy management (MTM) services provided by pharmacists and expanding home infusion in Medicare to cover the supplies, equipment and services. HR 2350 the Preserving Patient Access to Primary Care Act of 2009 all provisions; regarding increasing the number of primary care physicians and primary care providers, such as nurse practitioners and physician assistants, to improve patient access to primary care services.

Agencies Lobbied

Type of Issue

4th Quarter, 2009

Q4 Report

In Q4, WALGREEN CO. had in-house lobbyists. The report was filed on Jan. 20, 2010. Original Filing: 300243975.xml

Lobbying Issues

S. 391/HR. 1321 - the "Healthy American's Act" regarding the role of pharmacy in healthcare and Title VI regarding shared responsibilities.HR. 816 the Military Retirees Health Care Protection Act, Section 3, all provisions relating to a prohibition on increasing the cost sharing requirement under the pharmacy benefits program and a prohibition on increasing premiums under TRICARE. S. 80 the Pharmaceutical Market Access Act of 2009, all provisions; regarding amending the federal food, drug, and cosmetic act to allow pharmacies to import qualifying drugs from certain countries into the United States. S. 1232/S. 525/HR. 1298 the Pharmaceutical Market Access and Drug Safety Act of 2009 all provisions; regarding amending the federal food, drug, and cosmetic act to allow the importation of prescription drugs by pharmacies. MedGuides regarding improvement needed to the Medication Guide Program no specific legislation. Electronic Prescribing of Controlled Substances regarding the need for the DEA to publish rules that would allow for electronic prescribing of controlled substances no specific legislation. HR. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug and Device Safety all provisions relating to this title on drug and device safety. HR. 806 the Tricare Mail Order Pharmacy Pilot Program Act, all provisions; regarding establishing a mail-order pharmacy pilot program for Tricare beneficiaries.

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 1259 the Dextromethorphan Distribution Act of 2009 all provisions of the bill; regarding amending the federal food, drug, and cosmetic act to limit the distribution and abuse of DXM.HR. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug Safety provisions relating to country of origin labeling for drugs and devices. HR. 1548 the Pathway for Biosimilars Act all provisions; regarding establishing a pathway at the Food and Drug Administration for the approval of generic versions of biotech pharmaceuticals. S. 726/HR. 1427 the Promoting Innovation and Access to Life-Saving Medicine Act - all provisions; regarding establishing a pathway at the Food and Drug Administration for the approval of generic versions of biotech pharmaceuticals. HR. 1815 the Consumer Product Safety Solutions Act Section 2 provision relating to lead limits and third party testing requirements, Section 3 provisions relating to phthalates prohibition, Section 4 provisions relating to clarification of testing methodologies, Section 5 provisions relating to the exclusion of certain materials from lead content limit, Section 6 provision relating to the waiver of third party testing requirements for certain component parts, Section 7 provisions relating to exemptions from tracing label requirements, Section 8- provisions relating to the general application and exemptive authority of the Consumer Product Safety Commission. S. 882 the Drug and Device Accountability Act of 2009 Title I Ensuing the safety and quality of medical products and their components all provisions relating to this title on drug and device safety. S. 1383 the Dextromethorphan Abuse Reduction Act of 2009 all provisions; regarding amending the Controlled Substances Act to prevent the abuse of dextromethorphan.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S.701/HR. 2002 the Medicare Patient IVIG Access Act of 2009 Section 4, provisions relating to coverage of home administration of IVIG and reimbursement for services, supplies and equipment.Pharmacy enhancements for consideration to the Medicare Modernization Act no specific legislation. HR. 1765 all provisions, regarding amending the Social Security Act with respect to payment for items and services relating to the furnishing of IVIG in a patients home for the treatment of primary immune deficiency disease and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare program. HR. 203 the Medicare Fraud Prevention Act of 2009 Section 4 provisions relating to the increased surety bond requirement of suppliers of durable medical equipment. S. 956/HR 1970 the Preserve Patient Access to Reputable DMEPOS Providers Act of 2009 all provisions; regarding exempting unsanctioned State-licensed retail pharmacies from the surety bond requirement under the Medicare Program for suppliers of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS). HR 574/S. 254 the Medicare Home Infusion Therapy Act of 2009 all provisions; regarding amending the Social Security Act to provide for the coverage of home infusion therapy under the Medicare program. HR. 3108 the Medication Therapy Management Benefits Act of 2009, all provisions; regarding amending part D of title XVIII of the Social Security Act to promote medication therapy management under the Medicare part D prescription drug program. HR. 3663 all provisions; regarding amending title XVIII of the Social Security Act to delay the date on which the accreditation requirement under the Medicare Program applies to suppliers of durable medical equipment that are pharmacies.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Walgreens and its subsidiaries can impact efforts in health care reform with regards to access, affordability and quality.S. 1796, the Americas Healthy Future Act of 2009 regarding redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies as related to AMPs Federal Upper Limits (FULs), regarding expanding medication therapy management (MTM) services provided by pharmacists and expanding home infusion in Medicare to cover the supplies, equipment and services. S. 1679, the Affordable Health Choices Act - health care reform legislation introduced by Senator Edward Kennedy; regarding expanding medication therapy management (MTM) services provided by pharmacists also the establishment of a grant program to implement MTM for the treatment of chronic diseases. HR. 3200, the Americas Affordable Health Choices Act of 2009 regarding redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies as related to AMPs Federal Upper Limits (FULs), expanding home infusion in Medicare to cover the supplies, equipment and services, and regarding expanding medication therapy management (MTM) services provided by pharmacists. H.R. 3962, the Affordable Health Care for America Act- regarding redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies- as related to AMPs Federal Upper Limits (FULs), regarding expanding medication therapy management (MTM) services provided by pharmacists and expanding home infusion in Medicare to cover the supplies, equipment and services. HR 3590, the Patient Protection and Affordable Care Act- regarding redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies- as related to AMPs Federal Upper Limits (FULs), regarding expanding medication therapy management (MTM) services provided by pharmacists and expanding home infusion in Medicare to cover the supplies, equipment and services. HR 2350 the Preserving Patient Access to Primary Care Act of 2009 all provisions; regarding increasing the number of primary care physicians and primary care providers, such as nurse practitioners and physician assistants, to improve patient access to primary care services.

Agencies Lobbied

Type of Issue

3rd Quarter, 2009

Q3 Report

In Q3, WALGREEN CO. had in-house lobbyists. The report was filed on Oct. 19, 2009. Original Filing: 300213096.xml

Lobbying Issues

S. 391/HR. 1321 the Healthy Americans Act regarding the role of pharmacy in healthcare and Title VI regarding shared responsibilities. HR. 816 the Military Retirees Health Care Protection Act, Section 3, all provisions relating to a prohibition on increasing the cost sharing requirement under the pharmacy benefits program and a prohibition on increasing premiums under TRICARE. S. 80 the Pharmaceutical Market Access Act of 2009, all provisions; regarding amending the federal food, drug, and cosmetic act to allow pharmacies to import qualifying drugs from certain countries into the United States. S. 1232/S. 525/HR. 1298 the Pharmaceutical Market Access and Drug Safety Act of 2009 all provisions; regarding amending the federal food, drug, and cosmetic act to allow the importation of prescription drugs by pharmacies. MedGuides regarding improvement needed to the Medication Guide Program no specific legislation. Electronic Prescribing of Controlled Substances regarding the need for the DEA to publish rules that would allow for electronic prescribing of controlled substances no specific legislation. HR. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug and Device Safety all provisions relating to this title on drug and device safety. HR. 806 the TRICARE Mail Order Pharmacy Pilot Program Act, all provisions; regarding establishing a mail-order pharmacy pilot program for TRICAREe beneficiaries.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Walgreens and its subsidiaries can impact efforts in health care reform with regards to access, affordability and quality.Senate Finance Committee Health Reform Plan -Americas Healthy Future Act of 2009 regarding redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies as related to AMPs Federal Upper Limits (FULs), regarding expanding medication therapy management (MTM) services provided by pharmacists and expanding home infusion in Medicare to cover the supplies, equipment and services. S. 1679, the Affordable Health Choices Act - health care reform legislation introduced by Senator Edward Kennedy; regarding expanding medication therapy management (MTM) services provided by pharmacists also the establishment of a grant program to implement MTM for the treatment of chronic diseases. HR. 3200, the Americas Affordable Health Choices Act of 2009 regarding redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies as related to AMPs Federal Upper Limits (FULs), expanding home infusion in Medicare to cover the supplies, equipment and services, and regarding expanding medication therapy management (MTM) services provided by pharmacists. HR 2350 the Preserving Patient Access to Primary Care Act of 2009 all provisions; regarding increasing the number of primary care physicians and primary care providers, such as nurse practitioners and physician assistants, to improve patient access to primary care services.

Agencies Lobbied

Type of Issue

2nd Quarter, 2009

Q2 Report

In Q2, WALGREEN CO. had in-house lobbyists. The report was filed on July 20, 2009. Original Filing: 300189703.xml

Lobbying Issues

S. 391/HR. 1321 the Healthy Americans Act regarding the role of pharmacy in healthcare and Title VI regarding shared responsibilities. HR. 816 the Military Retirees Health Care Protection Act, Section 3, all provisions relating to a prohibition on increasing the cost sharing requirement under the pharmacy benefits program and a prohibition on increasing premiums under TRICARE. Medicaid reimbursement for generic drugs relating to redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies- as related to AMPs Federal Upper Limits (FULs) no specific legislation. S. 80 the Pharmaceutical Market Access Act of 2009, all provisions; regarding amending the federal food, drug, and cosmetic act to allow pharmacies to import qualifying drugs from certain countries into the United States. S. 525/HR. 1298 the Pharmaceutical Market Access and Drug Safety Act of 2009 all provisions; regarding amending the federal food, drug, and cosmetic act to allow the importation of prescription drugs by pharmacies. MedGuides regarding improvement needed to the Medication Guide Program no specific legislation. Electronic Prescribing of Controlled Substances regarding the need for the DEA to publish rules that would allow for electronic prescribing of controlled substances no specific legislation. HR. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug and Device Safety all provisions relating to this title on drug and device safety. HR. 806 the Tricare Mail Order Pharmacy Pilot Program Act, all provisions; regarding establishing a mail-order pharmacy pilot program for Tricare beneficiaries.

Agencies Lobbied

Type of Issue

Lobbying Issues

HR 1259 the Dextromethorphan Distribution Act of 2009 all provisions of the bill; regarding amending the federal food, drug, and cosmetic act to limit the distribution and abuse of DXM.HR. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug Safety provisions relating to country of origin labeling for drugs and devices. HR. 1548 the Pathway for Biosimilars Act all provisions; regarding establishing a pathway at the Food and Drug Administration for the approval of generic versions of biotech pharmaceuticals. S. 726/HR. 1427 the Promoting Innovation and Access to Life-Saving Medicine Act - all provisions; regarding establishing a pathway at the Food and Drug Administration for the approval of generic versions of biotech pharmaceuticals. HR. 1815 the Consumer Product Safety Solutions Act Section 2 provision relating to lead limits and third party testing requirements, Section 3 provisions relating to phthalates prohibition, Section 4 provisions relating to clarification of testing methodologies, Section 5 provisions relating to the exclusion of certain materials from lead content limit, Section 6 provision relating to the waiver of third party testing requirements for certain component parts, Section 7 provisions relating to exemptions from tracing label requirements, Section 8- provisions relating to the general application and exemptive authority of the Consumer Product Safety Commission. HR. 1256 the Family Smoking Prevention and Tobacco Control Act. Title II provisions relating to labeling and marketing of tobacco products, provisions relating to labeling and marketing of smokeless tobacco products, Title III provisions relating to the labeling, recordkeeping and records inspection of tobacco products. S. 882 the Drug and Device Accountability Act of 2009 Title I Ensuing the safety and quality of medical products and their components all provisions relating to this title on drug and device safety. S. 1383 the Dextromethorphan Abuse Reduction Act of 2009 all provisions; regarding amending the Controlled Substances Act to prevent the abuse of dextromethorphan.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S.701 the Medicare Patient IVIG Access Act of 2009 Section 4, provisions relating to coverage of home administration of IVIG and reimbursement for services, supplies and equipment.Pharmacy enhancements for consideration to the Medicare Modernization Act no specific legislation. HR. 1765 all provisions, regarding amending the Social Security Act with respect to payment for items and services relating to the furnishing of IVIG in a patients home for the treatment of primary immune deficiency disease and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare program. HR. 203 the Medicare Fraud Prevention Act of 2009 Section 4 provisions relating to the increased surety bond requirement of suppliers of durable medical equipment. S. 956/HR 1970 the Preserve Patient Access to Reputable DMEPOS Providers Act of 2009 all provisions; regarding exempting unsanctioned State-licensed retail pharmacies from the surety bond requirement under the Medicare Program for suppliers of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS). HR 574/S. 254 the Medicare Home Infusion Therapy Act of 2009 all provisions; regarding amending the Social Security Act to provide for the coverage of home infusion therapy under the Medicare program.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Walgreens and its subsidiaries can impact efforts in health care reform with regards to access, affordability and quality. Senate Finance Policy Options Paper regarding redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies as related to AMPs Federal Upper Limits (FULs), regarding expanding medication therapy management (MTM) services provided by pharmacists and expanding home infusion in Medicare to cover the supplies, equipment and services, the role of nurse practioners, retail clinics and employer workite facilities in health care reform no specific legislation. American Health Choices Act draft health care reform legislation introduced by Senator Edward Kennedy; regarding expanding medication therapy management (MTM) services provided by pharmacists also the establishment of a grant program to implement MTM for the treatment of chronic diseases. House Tri-Committee Health Care Reform Draft regarding redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies as related to AMPs Federal Upper Limits (FULs), expanding home infusion in Medicare to cover the supplies, equipment and services, and regarding expanding medication therapy management (MTM) services provided by pharmacists. HR 2350 the Preserving Patient Access to Primary Care Act of 2009 all provisions; regarding increasing the number of primary care physicians and primary care providers, such as nurse practitioners and physician assistants, to improve patient access to primary care services.

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Q1 Report

In Q1, WALGREEN CO. had in-house lobbyists. The report was filed on April 20, 2009. Original Filing: 300162543.xml

Lobbying Issues

H.R. 1 the American Recovery and Reinvestment Act of 2009- Title IV, all provisions relating to Health Information Technology, Title V, all provisions relating to Medicaid FMAP; S. 391/HR. 1321 the Healthy Americans Act regarding the role of pharmacy in healthcare and Title VI regarding shared responsibilities;H.R. 816 the Military Retirees Health Care Protection Act, Section 3, all provisions relating to a prohibition on increasing the cost sharing requirement under the pharmacy benefits program and a prohibition on increasing premiums under TRICARE; Medicaid reimbursement for generic drugs relating to accurately defining Average Manufacturers Price (AMP) to reflect purchase price of retail pharmacies to ensure appropriate reimbursement no specific legislation; S. 80 the Pharmaceutical Market Access Act of 2009, all provisions; regarding amending the federal food, drug and cosmetic act to allow pharmacies to import qualifying drugs from certain countries into the United States; S. 525/H.R. 1298 the Pharmaceutical Market Access and Drug Safety Act of 2009 all provisions regarding amending the federal food, drug and cosmetic act to allow the importation of prescription drugs by pharmacies; MedGuides regarding improvement needed to the Medication Guide Program no specific legislation; Electronic Prescribing of Controlled Substances regarding the need for the DEA to publish a workable rule that would allow for electronic prescribing of controlled substances no specific legislation; H.R. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug and Device Safety all provisions relating to drug and device safety; H.R. 570 the Protecting Patients and Health Care Act of 2009 all provisions regarding nullifying regulations issued by the Secretary of Health and Human Services regarding conscience clause protections for health care workers and facilities; H.R. 1548 the Pathway for Biosimilars Act all provisions; regarding establishing a pathway at the Food and Drug Administration for the approval of generic versions of biopharmaceuticals; S. 726/H.R. 1427 the Promoting Innovation and Access to Life-Saving Medicine Act - all provisions; regarding establishing a pathway at the Food and Drug Administration for the approval of generic versions of biopharmaceuticals.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 759 - the "Food and Drug Administration Globalization Act of 2009" - Title II - Drug and Device Safety - provisions relating to country of origin labeling for drugs and devices;H.R. 1815 the Consumer Product Safety Solutions Act Section 2 provisions relating to lead limits and third party testing requirements, Section 3 provisions relating to phthalates prohibition, Section 4 provisions relating to clarification of testing methodologies, Section 5 provisions relating to the exclusion of certain materials from lead content limit, Section 6 provisions relating to the waiver of third party testing requirements for certain component parts, Section 7 provisions relating to exemptions from tracking label requirements, Section 8- provisions relating to the general application and exemptive authority of the Consumer Product Safety Commission.

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1173 the Organized Retail Crime Act of 2009 all provisions, regarding amending title 18 of the United States Criminal Code to include organized retail crime and imposing requirements on on-line marketplaces to aid in criminal investigations; S. 470 the Combating Organized Retail Crime Act of 2009 all provisions, regarding amending the criminal code and expanding the definition of transporting and selling stolen goods from a physical or on-line marketplace;H.R. 1166 the E-Fencing Enforcement Act of 2009 all provisions, regarding amending the criminal code to impose duty on on-line marketplaces to retain contact information on high volume sellers and disclose that information when evidence is presented by law enforcement regarding stolen merchandise.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2008

Q4 Report

In Q4, WALGREEN CO. had in-house lobbyists. The report was filed on Jan. 21, 2009. Original Filing: 300131500.xml

Lobbying Issues

S.1951/H.R. 3700 Fair Medicaid Drug Payment Act of 2007 regarding Medicaid reimbursement for generic drugs as related to average manufacturers price (AMP) and federal upper limits (FULs); H.R. 3140 Saving Our Community Pharmacies Act of 2007 regarding Medicaid reimbursement of generic drugs as related to AMP and FULs; S. 334 Healthy Americans Act regarding the role of pharmacy in healthcare and Title VI regarding shared responsibilities;S.980/H.R. 6353 Online Pharmacy Consumer Protection Act of 2007 regarding amendments to the Control Substances Act relating to the delivery of control substances over the internet; S.3101/H.R. 6331 Medicare Improvements for Patients and Providers Act of 2008 Sec. 132 regarding incentives for electronic prescribing, Sec. 171 regarding prompt pay by PDPs and MA-PDs for prescriptions dispensed in Medicare Part D, Sec. 203 regarding reimbursement for generic drugs dispensed in the Medicaid program; S. 2408 "E-Meds Act of 2007 regarding amendments to the Social Security Act requiring physicians to utilize electronic prescribing for Medicare prescriptions; H.R. 2900 Food and Drug Amendments Act of 2007 Sec. 910 regarding pharmaceutical safety; H.R. 5839 Safeguarding Americas Pharmaceuticals Act of 2008 regarding amending the Food, Drug & Cosmetics Act to improve the safety of drugs; Electronic Prescribing of Controlled Substances regarding the need for the DEA to publish rules that would allow for electronic prescribing of controlled substances no specific legislation; S. 3001/ H.R. 5658 National Defense Authorization Act for Fiscal Year 2009 Sec. 702 regarding a freeze on current copays at retail pharmacies for medications dispensed in the TRICARE pharmacy program; MedGuides regarding improvements needed to the Medication Guide program no specific legislation; S. 1693 Wired for Healthcare Quality Act of 2007- Title IV Sec 401 Privacy and Security regarding changes in the definition of marketing under HIPAA and breach notification; H.R. 6357 PRO(TECH)T Act of 2008 - Title III regarding impact of privacy and security provisions on pharnacies, H.R. 6898 Health-e Information Technology Act of 2008 - Title IV regarding impact of privacy and security provisions on pharmacies.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2008

Q3 Report

In Q3, WALGREEN CO. had in-house lobbyists. The report was filed on Oct. 17, 2008. Original Filing: 300098656.xml

Lobbying Issues

S.1951/H.R. 3700 Fair Medicaid Drug Payment Act of 2007 regarding Medicaid reimbursement for generic drugs as related to average manufacturers price (AMP) and federal upper limits (FULs); H.R. 3140 Saving Our Community Pharmacies Act of 2007 regarding Medicaid reimbursement of generic drugs as related to AMP and FULs; S. 334 Healthy Americans Act regarding the role of pharmacy in healthcare and Title VI regarding shared responsibilities; S.980/H... 6353 Online Pharmacy Consumer Protection Act of 2007 regarding amendments to the control substances act relating to the delivery of control substances over the internet; S.3101/H.R. 6331 Medicare Improvements for Patients and Providers Act of 2008 Sec. 132 regarding incentives for electronic prescribing, Sec. 171 regarding prompt pay by PDPs and MA-PDs for prescriptions dispensed in Medicare Part D, Sec. 203 regarding reimbursement for generic drugs dispensed in the Medicaid program; S. 2408 "E-Meds Act of 2007 regarding amendments to the Social Security Act requiring physicians to utilize electronic prescribing for Medicare prescriptions; H.R. 2900 Food and Drug Amendments Act of 2007 Sec. 910 regarding pharmaceutical safety; H.R. 5839 Safeguarding Americas Pharmaceuticals Act of 2008 regarding amending the Food, Drug & Cosmetics Act to improve the safety of drugs; Electronic Prescribing of Controlled Substances regarding the need for the DEA to publish rules that would allow for electronic prescribing of controlled substances no specific legislation; S. 3001/ H.R. 5658 National Defense Authorization Act for Fiscal Year 2009 Sec. 702 regarding a freeze on current copays at retail pharmacies for medications dispensed in the TRICARE pharmacy program; MedGuides regarding improvements needed to the Medication Guide program no specific legislation; S. 1693 Wired for Healthcare Quality Act of 2007- Title IV Sec 401 Privacy and Security regarding changes in the definition of marketing under HIPAA and breach notification; H.R. 6357 PRO(TECH)T Act of 2008 - Title III regarding impact of privacy and security provisions on pharnacies, H.R. 6898 Health-e Information Technology Act of 2008 - Title IV regarding impact of privacy and security provisions on pharmacies.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2008

Q2 Report

In Q2, WALGREEN CO. had in-house lobbyists. The report was filed on July 18, 2008. Original Filing: 300073841.xml

Lobbying Issues

S. 1951/H.R. 3700 the "Fair Medicaid Drug Payment Act of 2007" - Medicaid reimbursement for generic drugs as related to average manufacturer's price (AMP) and federal upper limits (FULs); H.R. 3140 "Saving Our Community Pharmacies Act of 2007" - Medicaid reimbursement for generic drugs as related to AMP and FULs; S. 980 the "Online Pharmacy Consumer Protection Act of 2007" - regarding amendments to the control substances act relating to the delivery of control substances over the internet; S. 3101 the "Medicare Improvements for Patients and Providers Act of 2008" - Sec. 132 regarding incentives for electronic prescribing, Sec. 171 regarding prompt pay by PDP's and MA-PD's for prescriptions dispensed in Medicare Part D, Sec. 203 regarding reimbursement for generic drugs dispensed in the Medicaid program; H.R. 6331 the "Medicare Improvements for Patients and Providers Act of 2008" - Sec. 132 regarding incentives for electronic prescribing, Sec. 171 regarding prompt pay by PDP's and MA-PD's for prescriptions dispensed in Medicare Part D, Sec. 203 regarding reimbursement for generic drugs dispensed in the Medicaid program; S. 2408 the "E-Meds Act of 2007" regarding amendments to the Social Security Act requiring physicians to utilize electronic prescribing for Medicare prescriptions; H.R. 3580 the 'Food and Drug Administration Amendments Act of 2007" - Sec 505d regarding pharmaceutical safety and anti-counterfeiting; S. 1082 the "FDA Revitalization Act of 2007" - Sec. 514 regarding anti-counterfeiting technology, Sec. 807 regarding internet pharmacy; H.R. 2900 the "Food and Drug Amendments Act of 2007" - Sec. 910 regarding pharmaceutical safety; H.R. 5839 the "Safeguarding America's Pharmaceuticals Act of 2008" regarding amending the Food, Drug & Cosmetics Act to improve the safety of drugs; Electronic Prescribing of Controlled Substances - regarding the need for the DEA to publish rules that would allow for electronic prescribing of controlled substances - no specific legislation; H.R. 5658 the "Duncan Hunter National Defense Authorization Act for Fiscal Year 2009" - Sec. 702 regarding a freeze on current copays at retail pharmacies for medications dispensed in the TRICARE pharmacy program; MedGuides - regarding improvements needed to the Medication Guide program - no specific legislation.

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 1276/H.R. 2747 the "Methamphetamine Production Prevention Act of 2007" - electronic logbooks, tracking systems; H.R. 3610 the "Food and Drug Import Safety Act of 2007" - Sec. 6 regarding country of origin labeling for drugs and devices; S. 2274 the "Dextromethrophan Abuse Reduction Act of 2007" - regarding amending the Controlled Substances Act to prevent the abuse of DXM, limiting sales to those over the age of 18; S. 2045 the "Consumer Product Safety Commission Reform Act of 2007" - Sec. 23 (e) regarding the implementation of new lead standards; S. 1693 the "Wired for Healthcare Quality Act of 2007" Title IV, Sec 401 Privacy and Security regarding changes in the definition of marketing under HIPAA and breach notification; House HIT discussion draft regarding changes to the definition of marketing under HIPAA, breach notification and accounting of electronic disclosures.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2008

Q1 Report

In Q1, WALGREEN CO. had in-house lobbyists. The report was filed on April 21, 2008. Original Filing: 300054451.xml

Lobbying Issues

S. 1951/H.R. 3700 the "Fair Medicaid Drug Payment Act of 2007" - Medicaid reimbursement for generic drugs as related to average manufacturer's price (AMP) and federal upper limits (FULs); H.R. 3140 "Saving Our Community Pharmacies Act of 2007" - Medicaid reimbursement for generic drugs as related to AMP and FULs; S. 980 the "Online Pharmacy Consumer Protection Act of 2007" - regarding amendments to the control substances act relating to the delivery of control substances over the internet; S. 2408 the "E-Meds Act of 2007" - e-prescribing in Medicare - regarding amendments to the Social Security Act requiring physicians to utilize electronic prescribing for Medicare prescriptions; H.R. 3580 the 'Food and Drug Administration Amendments Act of 2007" - Sec 505d regarding pharmaceutical safety and anti-counterfeiting; S. 1082 the "FDA Revitalization Act of 2007" -Sec. 514 regarding anti-counterfeiting technology, Sec. 807 internet pharmacy, MedGuides for prescription drugs; H.R. 2900 the "Food and Drug Amendments Act of 2007" - Sec. 910 regarding pharmaceutical safety, MedGuides for prescription drugs; H.R.5491 the "Pharmacy Technician Training and Registration Act of 2008 regarding grant programs to allow states to establish and implement technician registration programs; H.R. 5629 the "Pathway to Biosimilars Act" regarding licensure pathway for biogenerics; H.R. 1956 the "Patient Protection and Innovative Biologic Medicines Act of 2007" regarding amending the Public Health Service Act to provide for approval of biosimilar products; S. 1145 the "Patent Reform Act of 2007" Sec 12 regarding inequitable conduct and the development of a pathway for approval of biogenerics; Electronic Prescribing of Controlled Substances - regarding the need for the DEA to publish rules that would allow for electronic prescribing of controlled substances - no specific legislation; TRICARE pharmacy program as it relates to Federal Supply Schedule pricing for drugs dispensed in retail pharmacies and the copays at retail pharmacy - no specific legislation

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 1276/H.R. 2747 the "Methamphetamine Production Prevention Act of 2007" - electronic logbooks, tracking systems; H.R. 3610 the "Food and Drug Import Safety Act of 2007" - Sec. 6 regarding country of origin labeling for drugs and devices; S. 2274 the "Dextromethrophan Abuse Reduction Act of 2007" - regarding amending the Controlled Substances Act to prevent the abuse of DXM, limiting sales to those over the age of 18; S. 2045 the "Consumer Product Safety Commission Reform Act of 2007" - Sec. 23 (e) regarding the implementation of new lead standards; H.R. 1108 the "Family Smoking Prevention and Tobacco Control Act" Title I, Chapter IX Sec. 913 regarding equal treatment of retail outlets and Sec 917 regarding preservation of state and local authority.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2006

Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Legislators

Bills

Statements

Lobbying

Travel

Lobbyists

Disclosures Filed